At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

Monitoring Duchenne muscular dystrophy helps ensure timely treatment. ... Your child should have a dual-energy X-ray absorptiometry (DEXA) test to measure bone density every 2-3 years.

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

Like Duchenne muscular dystrophy, Becker muscular dystrophy typically affects only males (1 in 30,000) and causes heart problems. Disease severity varies. Those with Becker can usually walk into ...

A new gene therapy for Duchenne muscular dystrophy (DMD) has shown promise in not only slowing the progression of the disease but potentially even reversing the muscle damage.

Dysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to ...

While genetic testing could not confirm Duchenne muscular dystrophy, a muscle biopsy at UCLA did. "He could see that he was declining, and that it was getting worse," said Stephanie.

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

The one-time treatment is approved for children with a genetic variant of Duchenne’s muscular dystrophy, which causes weakness, loss of mobility and early death in males.

The Sapp family pose for a photo while on a family vacation. Amber Sapp, a St. Petersburg resident, is a physical therapist and mom to 18-year-old Garrett, who lives with Duchenne muscular dystrophy.